NASDAQ:AVBP
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. reported net income of −$166.3M in fiscal 2025. The diluted share count rose 22.2%.Summary generated from ArriVent BioPharma, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−58.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+22.2%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −75 | −94 | −178 |
| Net income | −69 | −80 | −166 |
| Free cash flow | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Oct 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KEntry into a material agreement
Aug 12, 2026 - 4Insider transaction report
Jun 22, 2026 - 4Insider transaction report
Jun 22, 2026 - 8-KResults of a shareholder vote
Jun 22, 2026 - 8-KOther events
May 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 11, 2026